EYPT logo

EYPT
EyePoint Pharmaceuticals Inc

8,743
Mkt Cap
$1.18B
Volume
742,028.00
52W High
$19.11
52W Low
$5.14
PE Ratio
-4.49
EYPT Fundamentals
Price
$14.19
Prev Close
$14.23
Open
$14.29
50D MA
$14.36
Beta
1.24
Avg. Volume
1.3M
EPS (Annual)
-$3.17
P/B
3.84
Rev/Employee
$146,593.46
$1,055.00
Loading...
Loading...
News
all
press releases
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by Brokerages
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has earned a consensus recommendation of "Buy" from the eight brokerages that are currently covering the company, Marketbeat reports...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 3.7% - Time to Sell?
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 3.7% - Time to Sell...
MarketBeat·6d ago
News Placeholder
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT
Aberdeen Group plc boosted its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 101.6% in the 4th quarter, according to its most recent filing with the Securities and...
MarketBeat·6d ago
News Placeholder
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·10d ago
News Placeholder
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference
Executives from Eyepoint Pharmaceuticals (NASDAQ:EYPT) told investors at RBC Capital Markets' Ophthalmology Conference that the company's lead program, DURAVYU (vorolanib), is advancing through four...
MarketBeat·18d ago
News Placeholder
Insider Buying: Eyepoint Pharmaceuticals (NASDAQ:EYPT) CEO Buys 1,500 Shares of Stock
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) CEO Jay Duker acquired 1,500 shares of Eyepoint Pharmaceuticals stock in a transaction dated Monday, March 16th. The shares were...
MarketBeat·27d ago
News Placeholder
Rosalind Advisors Inc. Acquires Shares of 650,000 Eyepoint Pharmaceuticals, Inc. $EYPT
Rosalind Advisors Inc. acquired a new position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC...
MarketBeat·1mo ago
News Placeholder
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are covering the company, Marketbeat reports. One...
MarketBeat·1mo ago
News Placeholder
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 9.1% - Here's Why
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 9.1% - Should You Sell...
MarketBeat·1mo ago
News Placeholder
Citigroup Boosts Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $35.00
Citigroup lifted their target price on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Monday...
MarketBeat·1mo ago
<
1
2
...
>

Latest EYPT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.